GPhA: AbbVie's Petition On US Biosimilars A Ploy To Delay Interchangeables
This article was originally published in SRA
Executive Summary
AbbVie Inc's citizen petition calling for a public hearing1 before the US Food and Drug Administration issues its long-awaited biosimilars guidance on interchangebility is nothing more than a "thinly disguised" ploy to block cheaper biologics that may be substituted for the brand-name products, the Generic Pharmaceutical Association (GPhA) and its affiliated Biosimilars Council argued in public comments submitted to the US regulatory agency.